Michael Fiegl

Summary

Affiliation: Innsbruck Medical University
Country: Austria

Publications

  1. ncbi request reprint Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients
    M Fiegl
    Department of Internal Medicine V, Hemato Oncology, Medical University of Innsbruck, Innsbruck, Austria Electronic address
    Lung Cancer 84:168-74. 2014
  2. doi request reprint Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
    M Fiegl
    Department of Internal Medicine V Hematology and Oncology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
    Ann Hematol 93:267-77. 2014
  3. doi request reprint Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study
    Michael Fiegl
    University Hospital, Medical University of Innsbruck, Innsbruck, Austria
    Curr Med Res Opin 29:505-15. 2013
  4. ncbi request reprint Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
    Michael Fiegl
    Department of Internal Medicine V, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    Ann Hematol 90:1083-91. 2011
  5. doi request reprint Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
    M Fiegl
    Department of Internal Medicine V, Medical University of Innsbruck, Austria
    Ann Oncol 21:2410-9. 2010
  6. pmc Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
    Michael Fiegl
    Department of Internal Medicine V Hematology Oncoloy, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, Austria
    BMC Cancer 11:373. 2011
  7. pmc Noninvasive detection of lung cancer by analysis of exhaled breath
    Amel Bajtarevic
    Department of Operative Medicine, Innsbruck Medical University, A 6020 Innsbruck, Austria
    BMC Cancer 9:348. 2009
  8. ncbi request reprint A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma
    Michael Mian
    Department of Hematology and Oncology, Medical University of Innsbruck, Austria
    Anticancer Res 34:2559-64. 2014
  9. ncbi request reprint Diminished quality of life in patients with cancer correlates with tryptophan degradation
    Katharina Schroecksnadel
    Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, 6020 Innsbruck, Austria
    J Cancer Res Clin Oncol 133:477-85. 2007
  10. ncbi request reprint Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement
    Andreas Pircher
    Medical University of Innsbruck, Department of Internal Medicine V, Anichstrasse 35, A 6020 Innsbruck, Austria
    Anticancer Res 33:3831-6. 2013

Detail Information

Publications26

  1. ncbi request reprint Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients
    M Fiegl
    Department of Internal Medicine V, Hemato Oncology, Medical University of Innsbruck, Innsbruck, Austria Electronic address
    Lung Cancer 84:168-74. 2014
    ..We postulated that SCLC patients might have benefitted from refined diagnosis and treatment options during the last decade...
  2. doi request reprint Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
    M Fiegl
    Department of Internal Medicine V Hematology and Oncology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
    Ann Hematol 93:267-77. 2014
    ..In conclusion, alemtuzumab administered even at low dose levels was effective but overall considerably toxic in routine CLL patients. We emphasize that alemtuzumab remains an important therapeutic option in subsets of CLL patients...
  3. doi request reprint Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study
    Michael Fiegl
    University Hospital, Medical University of Innsbruck, Innsbruck, Austria
    Curr Med Res Opin 29:505-15. 2013
    ..Guidelines for using granulocyte colony-stimulating factor (G-CSF) in patients receiving chemotherapies with 10-20% (intermediate) risk for febrile neutropenia (FN) recommend additional assessment of patient-related FN risk factors...
  4. ncbi request reprint Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
    Michael Fiegl
    Department of Internal Medicine V, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    Ann Hematol 90:1083-91. 2011
    ..We conclude that alemtuzumab retreatment represents an effective and tolerable therapeutic option for selected patients with CLL...
  5. doi request reprint Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
    M Fiegl
    Department of Internal Medicine V, Medical University of Innsbruck, Austria
    Ann Oncol 21:2410-9. 2010
    ..This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups...
  6. pmc Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
    Michael Fiegl
    Department of Internal Medicine V Hematology Oncoloy, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, Austria
    BMC Cancer 11:373. 2011
    ..Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy. PLD has demonstrated response activity even after prior anthracycline exposure...
  7. pmc Noninvasive detection of lung cancer by analysis of exhaled breath
    Amel Bajtarevic
    Department of Operative Medicine, Innsbruck Medical University, A 6020 Innsbruck, Austria
    BMC Cancer 9:348. 2009
    ..An early non-invasive diagnosis of lung cancer would improve prognosis and enlarge treatment options. Analysis of exhaled breath would be an ideal diagnostic method, since it is non-invasive and totally painless...
  8. ncbi request reprint A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma
    Michael Mian
    Department of Hematology and Oncology, Medical University of Innsbruck, Austria
    Anticancer Res 34:2559-64. 2014
    ..Finally, we confirm the independent impact of rituximab on the outcome of an unselected population with DLBCL. ..
  9. ncbi request reprint Diminished quality of life in patients with cancer correlates with tryptophan degradation
    Katharina Schroecksnadel
    Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, 6020 Innsbruck, Austria
    J Cancer Res Clin Oncol 133:477-85. 2007
    ..In this study, we compared QoL and fatigue self-rating scores of patients with various types of malignancy with tryptophan metabolic changes and immune activation status...
  10. ncbi request reprint Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement
    Andreas Pircher
    Medical University of Innsbruck, Department of Internal Medicine V, Anichstrasse 35, A 6020 Innsbruck, Austria
    Anticancer Res 33:3831-6. 2013
    ..Results of an observational study on docetaxel-based therapy in non-small cell lung cancer (NSCLC) with focus on symptom control and therapy response, are reported...
  11. pmc Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown
    Katharina Kurz
    Division of Biological Chemistry, Biocenter, Medical University, Innsbruck, Austria
    PLoS ONE 7:e36956. 2012
    ..Patients with cancer often suffer from fatigue and decreased quality of life which might be related to the breakdown of essential amino acid tryptophan...
  12. ncbi request reprint Inverse association between serum selenium concentrations and parameters of immune activation in patients with cardiac disorders
    Christian Murr
    Division of Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria
    Clin Chem Lab Med 45:1224-8. 2007
    ..The aim of this study was to determine the relationship between serum selenium concentrations and neopterin production and tryptophan degradation in patients with cardiac disorders...
  13. doi request reprint Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases
    William Sterlacci
    Institute for Pathology, Medical University Innsbruck, Muellerstrasse 44, 6020 Innsbruck, Austria
    Virchows Arch 455:125-32. 2009
    ..In conclusion, additional immunohistochemical detection of neuroendocrine differentiation in non-small cell lung cancer is presently not of prognostic importance and does not justify a distinct consideration...
  14. ncbi request reprint Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer
    Andreas Pircher
    Medical University of Innsbruck, Department of Internal Medicine V Haematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Anticancer Res 31:2949-55. 2011
    ..We retrospectively analysed data for 82 patients with advanced NSCLC treated with gefitinib and correlated benefits with clinical baseline and therapy-related parameters...
  15. pmc Angiogenesis in nodal B cell lymphomas: a high throughput study
    Alexandar Tzankov
    Institute of Pathology, Medical University of Innsbruck, Innsbruck, Austria
    J Clin Pathol 60:476-82. 2007
    ....
  16. doi request reprint Quality of life trajectory in patients with advanced cancer during the last year of life
    Johannes M Giesinger
    Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
    J Palliat Med 14:904-12. 2011
    ..Our study investigated the patient-reported severity of QOL impairments during the last year of life, with a special focus on their course at the end of life...
  17. ncbi request reprint Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria
    Michael Fiegl
    Department of Internal Medicine, Division of Hemato Oncology, University Hospital of Innsbruck, Innsbruck, Austria
    Cancer 107:2408-16. 2006
    ..In this retrospective study, the authors evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced, previously treated CLL who received treatment in the routine clinical setting...
  18. doi request reprint Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs)
    Andreas Pircher
    Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    Lung Cancer 81:252-8. 2013
    ..5 months and ECSCR high 120.5 vs. ECSCR low 42.2 months). In summary, we found that TEMs are overexpressed in NSCLC stromal tissue and that an increased TEM expression correlated with an increased overall survival in early stage NSCLC...
  19. ncbi request reprint [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]
    Wolfgang Hilbe
    Medizinische Universitat Innsbruck, Klinische Abteilung für Allgemeine Innere Medizin, Schwerpunkt Onkologie, Innsbruck, Austria
    Wien Klin Wochenschr 119:259-66. 2007
  20. doi request reprint "Idiopathic Bence-Jones proteinuria": a new characterization of an old entity
    Michael Mian
    Department of Hematology and Oncology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
    Ann Hematol 92:1263-70. 2013
    ..Our data suggest that MGUS+BJP being closer to malignant transformation may be due to the higher portion of genetically heterogeneous, pre-malignant plasma cell subclones...
  21. ncbi request reprint Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome
    Alexandar Tzankov
    Institutes of Pathology, Medical University of Innsbruck, Innsbruck, Austria
    Clin Cancer Res 12:2125-32. 2006
    ..Deregulation of cyclin E (CCNE) is a strong predictor of poor prognosis in some neoplastic diseases. In tumor cells, it induces chromosomal instability with an increased rate of aneuploidy/polyploidy...
  22. ncbi request reprint FISH cytogenetics and prognosis in breast and non-small cell lung cancers
    Anita Massoner
    Department of Internal Medicine, Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
    Cytometry B Clin Cytom 62:52-6. 2004
    ..As the next step, we investigated whether certain patterns of numeric aberrations in malignant effusion cells supply prognostic information...
  23. doi request reprint Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry
    Magdalena Ligor
    Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria
    Clin Chem Lab Med 47:550-60. 2009
    ..This might lead to a future diagnostic test for lung cancer...
  24. doi request reprint Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization
    Willam Sterlacci
    Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany Institute of Pathology, University Hospital Basel, Basel, Switzerland and Department of Internal Medicine, Division of Hematology and Oncology, Medical University Innsbruck, Austria
    J Thorac Oncol 9:41-9. 2014
    ..Proposed CSC markers are expressed both by cancer cells as well as by benign stem cells. Although many putative CSC markers exist, a precise characterization for non-small-cell lung cancer (NSCLC) is lacking...
  25. ncbi request reprint Hyperhomocysteinaemia and immune activation in patients with cancer
    Katharina Schroecksnadel
    Division of Biological Chemistry, Biocentre, Innsbruck Medical University, Innsbruck, Austria
    Clin Chem Lab Med 45:47-53. 2007
    ..Recently, homocysteine production was observed in tumour cell lines and homocysteine was proposed as a tumour marker. Furthermore, homocysteine production by activated immunocompetent cells was demonstrated...
  26. doi request reprint Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals
    Christian Waldthaler
    Department of Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
    Wien Klin Wochenschr 123:269-75. 2011
    ..The objective was to demonstrate feasibility and therapeutic efficacy of routine clinical use of the bendamustine/rituximab combination in lymphoproliferative diseases...